ライフサイエンスコーパス: stereotactic radiosurgery

1 ysicians counselling patients on Gamma Knife stereotactic radiosurgery.

2 melanoma; the surgical bed was treated with stereotactic radiosurgery.

3 clude surgery, whole-brain radiotherapy, and stereotactic radiosurgery.

4 find significant associations in studies of stereotactic radiosurgery.

5 otherapy (WBRT), with or without surgery, or stereotactic radiosurgery.

6 n radiation therapy, surgical resection, and stereotactic radiosurgery.

7 including conventional radiation as well as stereotactic radiosurgery.

8 ho underwent craniotomy followed by adjuvant stereotactic radiosurgery.

9 ients with 1-9 brain metastases treated with stereotactic radiosurgery (1-4 fractions) was performed.

10 66 (90%) of 73 metastases at 20 weeks after stereotactic radiosurgery; 61% maintained local control

11 ities, particularly image-guided surgery and stereotactic radiosurgery, allows clinicians who are foc

12 lar embolization, neurosurgical excision, or stereotactic radiosurgery alone or in combination).

13 TOG institutions--167 were assigned WBRT and stereotactic radiosurgery and 164 were allocated WBRT al

14 le evidence suggests the long-term safety of stereotactic radiosurgery and could support physicians c

15 roversial and can include surgical excision, stereotactic radiosurgery and embolization.

16 either (125)I interstitial brachy-therapy or stereotactic radiosurgery and is associated with a signi

17 adiation therapy (WBRT), surgical resection, stereotactic radiosurgery, and chemotherapy.

18 iew is focused on indications for resection, stereotactic radiosurgery, and fractionated radiotherapy

19 The new brain lesion was treated with stereotactic radiosurgery, and he began systemic therapy

20 hree-dimensional treatment planning systems, stereotactic radiosurgery, and intensity modulated radia

21 ion of endovascular embolisation techniques, stereotactic radiosurgery, and microsurgery, allowing ef

22 brain radiation therapy, surgical resection, stereotactic radiosurgery, and systemic therapy.

23 d therapy, such as whole-brain radiotherapy, stereotactic radiosurgery, and/or surgical resection.

24 Although surgery or stereotactic radiosurgery are highly effective local tre

25 rmations (CCMs) by neurosurgical excision or stereotactic radiosurgery are imprecise and vary between

26 Long-term effects, especially important for stereotactic radiosurgery, are unknown.

27 The incidence of stereotactic radiosurgery-associated intracranial malign

28 f the study was to estimate the incidence of stereotactic radiosurgery-associated intracranial malign

29 rquartile range, 0.02-0.18 cm(3)) undergoing stereotactic radiosurgery at one institution were includ

30 Of 14 168 patients who had Gamma Knife stereotactic radiosurgery between Aug 14, 1987, and Dec

31 radiation therapy (WBRT) or WBRT followed by stereotactic radiosurgery boost.

32 verification in preclinical CyberKnife-based stereotactic radiosurgery (CK-SRS) of intracranial tumor

33 combination of targeted agents or ICIs with stereotactic radiosurgery could further improve the resp

34 The use stereotactic radiosurgery for brain metastases has expan

35 paper will review the recent publications of stereotactic radiosurgery for brain tumors.

36 brain radiotherapy, and the role of upfront stereotactic radiosurgery for BrM.

37 proach towards predicting the outcomes after stereotactic radiosurgery for cerebral arteriovenous mal

38 Finally, as radiation therapy and stereotactic radiosurgery for pituitary tumors gains mor

39 with high-risk UM who underwent fractionated stereotactic radiosurgery (fSRS) treatment utilizing a n

40 ere was a survival advantage in the WBRT and stereotactic radiosurgery group for patients with a sing

41 Recently, stereotactic radiosurgery has emerged as an increasingly

42 Despite its controversial beginning, stereotactic radiosurgery has rapidly gained acceptance

43 Recent publications of stereotactic radiosurgery have increased our understandi

44 tumor is considered radiotherapy resistant, stereotactic radiosurgery is recommended; if the BMs are

45 A major concern of patients who have stereotactic radiosurgery is the long-term risk of havin

46 Stereotactic radiosurgery is the principal alternative t

47 e.g., first or redo transsphenoidal surgery, stereotactic radiosurgery) is limited by the inability o

48 Stereotactic radiosurgery may offer a survival advantage

49 3.3 years) and 5.4 (95% CI 4.5 to 6.4) after stereotactic radiosurgery (median follow-up 4.1 years).

50 adiosurgery is regarded as the gold-standard stereotactic radiosurgery modality for the treatment of

51 s, three received 13.5-18-Gy single-fraction stereotactic radiosurgery; one received 19.8 Gy in three

52 A total of 549 (14.0%) underwent stereotactic radiosurgery or whole brain radiotherapy fo

53 ic edema were a large tumor, single-fraction stereotactic radiosurgery, or use of more than 6 Gy per

54 Stereotactic radiosurgery planning for cerebral arteriov

55 We aimed to assess whether stereotactic radiosurgery provided any therapeutic benef

56 tive dexamethasone followed by pre-operative stereotactic radiosurgery (pSRS) and resection (n= 13 pe

57 the candidacy for focal therapy of BrM with stereotactic radiosurgery; reducing the toxicity and imp

58 of a benign tumour in patients treated with stereotactic radiosurgery remains low at long-term follo

59 leveraging the capabilities of image-guided stereotactic radiosurgery, separation surgery, vertebrop

60 WBRT and stereotactic radiosurgery should, therefore, be standard

61 es described, on behalf of the International Stereotactic Radiosurgery Society.

62 metastases and no systemic therapy options, stereotactic radiosurgery (SRS) alone should be offered

63 cation, resection can be challenging, making stereotactic radiosurgery (SRS) an attractive alternativ

64 Although stereotactic radiosurgery (SRS) and endovascular emboliz

65 npatients with brain metastases who received stereotactic radiosurgery (SRS) and/or non-SRS radiation

66 eatures and machine learning to predict post-stereotactic radiosurgery (SRS) brain metastasis (BM) pr

67 ergo whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS) delivered only to the ra

68 Adjuvant stereotactic radiosurgery (SRS) enhances the local contr

69 The optimal use of up-front stereotactic radiosurgery (SRS) for brain metastases (BM

70 sus guidelines recommend surgery followed by stereotactic radiosurgery (SRS) for lesions >3 cm, small

71 tiary care institution, 97% of whom received stereotactic radiosurgery (SRS) for local treatment of B

72 ding whole-brain radiation therapy (WBRT) to stereotactic radiosurgery (SRS) for the control of brain

73 he authors to explore the use of Gamma Knife stereotactic radiosurgery (SRS) for this common problem.

74 of hemorrhagic events in patients receiving Stereotactic Radiosurgery (SRS) for unruptured bAVMs.

75 Preoperative stereotactic radiosurgery (SRS) has been demonstrated as

76 Stereotactic radiosurgery (SRS) has been the cornerstone

77 Stereotactic radiosurgery (SRS) has evolved as widely ac

78 Stereotactic radiosurgery (SRS) has proven an effective

79 Stereotactic radiosurgery (SRS) is an established, effec

80 Within the guideline, stereotactic radiosurgery (SRS) is recommended for patie

81 Stereotactic radiosurgery (SRS) is the only local therap

82 s and retrospective series, neurosurgery and stereotactic radiosurgery (SRS) may prolong survival in

83 the large fractional doses that characterize stereotactic radiosurgery (SRS) or radiotherapy (SRT), s

84 We did this study to determine if stereotactic radiosurgery (SRS) to the surgical cavity i

85 However, stereotactic radiosurgery (SRS) to the surgical cavity i

86 in metastases are manually identified during stereotactic radiosurgery (SRS) treatment planning, whic

87 study compares patient outcomes treated with stereotactic radiosurgery (SRS) versus conservative mana

88 The concept of stereotactic radiosurgery (SRS) was first described by L

89 ntroversial and includes surgical resection, stereotactic radiosurgery (SRS), and whole-brain radiati

90 ency (PRF) of sphenopalatine ganglion (SPG), stereotactic radiosurgery (SRS), deep brain stimulation

91 Purpose Stereotactic radiosurgery (SRS), whole-brain radiotherap

92 ly improves tumor control in the brain after stereotactic radiosurgery (SRS), yet because of its asso

93 for patients with brain metastases following stereotactic radiosurgery (SRS).

94 patients received radiotherapy to the brain (stereotactic radiosurgery [SRS] or whole-brain radiother

95 paradigms has been the integration of spinal stereotactic radiosurgery (SSRS), allowing delivery of t

96 reatment, surgery, whole-brain radiotherapy, stereotactic radiosurgery, supportive or palliative care

97 htly more prolonged course of WBRT, surgery, stereotactic radiosurgery, systemic therapy, or a combin

98 le-brain radiotherapy and surgery to include stereotactic radiosurgery, targeted therapies and immuno

99 Currently, surgical excision and stereotactic radiosurgery, the primary treatment options

100 ion and influence treatment in patients with stereotactic radiosurgery-treated metastases.

101 apy (SBRT) is derived from the techniques of stereotactic radiosurgery used to treat lesions in the b

102 The median survival time after stereotactic radiosurgery was 53 weeks and correlated wi

103 institutions from Europe and the USA, after stereotactic radiosurgery was found to be similar to the

104 Rates of response to stereotactic radiosurgery were calculated.

105 ours, extraocular tumours, or other forms of stereotactic radiosurgery were excluded to reduce hetero

106 Five minipigs received focal stereotactic radiosurgery with single large doses of 40-